[ad_1]
Dublin, June 16, 2021 (Global News Agency) – “2021 Therapeutic Protein Global Market Report: Impact of COVID-19 and Recovery to 2030” Report has been added to ResearchAndMarkets.com provide.
The “2021 Therapeutic Protein Global Market Report: Impact and Recovery of COVID-19 in 2030” provides strategists, marketers, and senior management with the key information needed to evaluate the global therapeutic protein market, as the global therapeutic protein market is COVID-19 appeared after the closure.
The main players in the therapeutic protein market are Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd.
The global therapeutic protein market is expected to grow from USD 90.53 billion in 2020 to USD 98.1 billion in 2021, with a compound annual growth rate (CAGR) of 8.4%.
The growth was mainly due to the company rescheduling operations and recovering from the effects of COVID-19, which earlier led to restrictive containment measures, including social distancing, remote work, and the closure of business activities, which led to operational challenges . The market size is expected to reach USD 155.06 billion in 2025, with a compound annual growth rate of 12.1%.
The therapeutic protein market includes the sale of therapeutic proteins. Therapeutic proteins provide important treatments for diseases such as diabetes, cancer, infectious diseases, hemophilia and anemia.
The increase in biosimilars in the global market has slowed the growth of the therapeutic protein market. The expiration of patents for therapeutic proteins such as monoclonal antibodies provides space for the entry of biosimilars. In the European Union, AbbVie (AbbVie) proved that the patent of Humira (adalimumab) expired in 2018, and five biosimilars of Humira from Mylan, Amgen, Sandoz, and Samsung Bioepis Obtained the European Commission’s approval of the drug to enter the EU market. These cost-effective treatments similar to the original biologics have reduced the revenue and sales of therapeutic proteins.
In June 2018, Sanofi, a provider of therapeutic solutions, acquired Ablynx for US$4.8 billion. Through this acquisition, Sanofi strengthens its R&D strategy by adding Ablynx’s nanobody technology platform. Sanofi will also focus on technologies that use a single multispecific molecule to solve multiple disease targets. Ablynx is a biopharmaceutical company based in Ghent, Belgium, which develops proprietary therapeutic proteins based on single domain antibody fragments.
Advanced technologies for protein-based drug development are driving the therapeutic protein market. Therapeutic proteins cannot be synthesized chemically. They need to be produced in living cells or organisms through genetic engineering and recombinant DNA technology.
Protein engineering platform technologies such as glycoengineering, PEGylation, Fc fusion, albumin fusion, albumin drug coupling, etc. help to improve the yield, product purity, circulating half-life, targeting and functionality of therapeutic protein drugs. Belimumab, ipilimumab, taliglucerase alfa, albiglutide, coagulation factor IX recombinant human, etc. are some of the therapeutic protein drugs developed using FDA-approved protein engineering technology in the past five years.
In the United States, manufacturers of therapeutic protein drugs submit a therapeutic biologics application (BLA) to the FDA for product approval. Drugs approved by the BLA should be proven to be safe, pure and effective. FDA’s comprehensive review of most therapeutic proteins in the Center for Drug Evaluation and Research (CDER). In the European Union, biological products are regulated by the Committee on Medicinal Products for Human Use (CHMP) for marketing authorization.
In the field of protein therapy, the approval of monoclonal antibody drugs is increasing. The use of monoclonal antibodies can well treat chronic diseases such as cancer and immune diseases. Monoclonal antibodies are a dominant and mature product category in the field of protein therapy, and have higher safety and immunogenicity than antibodies.
Cell-based expression systems, such as the Chinese Hamster Ovary (CHO) mammalian cell expression system using the latest technology, overcome the problems associated with early antibody drugs and increase the productivity of monoclonal antibodies. In the past five years, the FDA has approved 213 drugs, 44 of which are monoclonal antibodies. In 2018, the FDA approved 12 monoclonal antibodies for the treatment of cancer and immune diseases.
Key topics covered:
1.executive Summary
2. Therapeutic protein market characteristics
3. Therapeutic protein market trends and strategies
4. The impact of COVID-19 on therapeutic protein
5. Therapeutic protein market size and growth
5.1. Global therapeutic protein historical market from 2015 to 2020, billion US dollars
5.1.1. Market drivers
5.1.2. Market restrictions
5.2. Global therapeutic protein forecast market, 2020-2025F, 2030F, billion US dollars
5.2.1. Market drivers
5.2.2. Market restrictions
6. Therapeutic protein market segmentation
6.1. Global therapeutic protein market, segmented by product type, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
- insulin
- Fusion protein
- Erythropoietin
- Interferon
- Human growth hormone
- Follicle Stimulating Hormone
6.2. Global therapeutic protein market, segmented by application, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
- Metabolic disorders
- Immune disease
- Blood disease
- cancer
- hormone imbalance
- Genetic disease
- other
6.3. The global therapeutic protein market, segmented by function, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
- Enzymatic and regulatory activity
- Special target activities
- vaccine
- Protein diagnosis
7. Therapeutic protein market region and country analysis
7.1. The global therapeutic protein market, divided by region, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
7.2. The global therapeutic protein market, divided by country, history and forecast, 2015-2020, 2020-2025F, 2030F, billion US dollars
Companies mentioned
- Abbott Laboratories
- Amgen
- Baxter International
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Pfizer
- Johnson & Johnson
- Merck
- Novo Nordisk A/S
- Sanofi
- Baijian Company
- Genentech
- General Biotechnology
- Gene technology
- Merck Serono
- AstraZeneca
- Boehringer Ingelheim
- Chugai Pharmaceutical
- Diasome Pharmaceutical
- Gene Science Pharmaceuticals
- Hualan Biological Engineering
- CSL Behring
- Concord Fermented Kirin
- Ogilvy
- Sandoz International
- Teva Pharmaceutical Industry
- AbbVie
- Bristol-Myers Squibb
- Novartis
- ProBiogen AG
For more information about this report, please visit https://www.researchandmarkets.com/r/z7542m
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
[ad_2]
Source link
